ºñ½ºÆ÷½ºÆ÷³×ÀÌÆ® °ü·Ã ¾Ç°ñ±«»ç¿¡ ´ëÇÑ ¿¬±¸: Áõ·Êº¸°í ¹× ¹®Çå¹®¼®
Study on bisphosphonate-related osteonecrosis of the jaw (BRONJ): case report and literature review
±è¿©°©, À̹é¼ö, ±Ç¿ë´ë, ¼ÁØÈ£, Áø»ó¹Ì,
¼Ò¼Ó »ó¼¼Á¤º¸
±è¿©°© ( Kim Yeo-Gap ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø ±¸°¾Ç¾È¸é¿Ü°úÇб³½Ç
À̹é¼ö ( Lee Baek-Soo ) - °æÈñ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°¾Ç¾È¸é¿Ü°úÇб³½Ç
±Ç¿ë´ë ( Kwon Yong-Dae ) - °æÈñ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°¾Ç¾È¸é¿Ü°úÇб³½Ç
¼ÁØÈ£ ( Suh Joon-Ho ) - °æÈñ´ëÇб³ Ä¡°ú´ëÇÐ ±¸°¾Ç¾È¸é¿Ü°ú
Áø»ó¹Ì ( Jeen Sang-Mi ) - °æÈñ´ëÇб³ Ä¡ÀÇÇÐÀü¹®´ëÇпø
KMID : 0355620100360040291
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of Bisphosphonates (BPs) use. These days, oral bisphosphonates are normally prescribed to treat osteoporosis. Intravenous BPs are used extensively to treat osteolytic bone lesions related to multiplemyeloma and bone metastasis of solid cancers, breast cancer or prostate cancer. As the prescription of BPs is universalized and the number of people treated with BPs is increasing, an accurate understanding and proper management of BRONJ are required. The aim of this study was to improve the linicians¡¯understanding of BRONJ by reviewing the literature. To achieve this, this paper introduces case reports as well as the current concept of BRONJ based on the 2009 updates by American Association of Oral and Maxillofacial (AAOMS) including the definition, epidemiology, etiology, diagnosis, treatment and prevention of BRONJ.
Å°¿öµå
Bisphosphonate; Osteonecrosis; Osteoporosis; Jaw diseases
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸